Danazol for treatment of refractory autoimmune hemolytic anaemia.

In: Annals of the Academy of Medicine, Singapore · 1989 · vol. 18(6) , pp. 707–9 · PMID:2624421 · W32337753
article OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed
AI-generated summary by claude@2026-06, 2026-06-13

This case study reports that danazol achieved excellent hematological remission in a pediatric patient with severe autoimmune hemolytic anemia refractory to steroids and splenectomy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Autoimmune hemolytic anemia (AHA) is uncommon in childhood. A female child presented with severe and chronic clinical course. She was refractory to steroid and the response to splenectomy was poor. She showed excellent remission of hematological condition with Danazol. Danazol may be the drug of choice for refractory autoimmune hemolytic anemia.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (2)

References (3)

Cited by (2)

Source provenance

openalex
last seen: 2026-05-10T18:01:37.864769+00:00
License: CC0 · commercial use OK